Hepatic Impairment
Conditions
Keywords
Mild Hepatic Impairment (HI), Moderate HI, Severe HI
Brief summary
The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.
Interventions
DRUGBPN14770
Administered as specified in the treatment arm.
Sponsors
Shionogi
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * Considered to be healthy (for healthy participants) or medically stable (for participants with hepatic impairment), as determined by medical evaluation. * Body weight ≥ 50 kilograms (kg) and body mass index (BMI) within the range ≥ 18.5 to \< 40.0 kilograms per square meter (kg/m\^2). * A diagnosis of clinically stable hepatic disease for at least 1 month prior to the screening visit, confirmed by medical history or previous confirmation of hepatic cirrhosis by liver biopsy or medical imaging technique. * Mild, moderate, and severe hepatic impairment based on the Child-Pugh classification score at the screening visit and Day ˗1 to determine eligibility: * Mild (Class A) hepatic impairment (Child-Pugh classification score 5 to 6) * Moderate (Class B) hepatic impairment (Child-Pugh classification score 7 to 9) * Severe (Class C) hepatic impairment (Child-Pugh classification score 10 to 15) * Healthy Participants matched to each participant with moderate hepatic impairment with respect to sex, age (± 10 years), and BMI (± 10%) Key
Exclusion criteria
* History or presence of/significant history of or current cardiovascular, respiratory, hepatic, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data, in the judgment of the investigator. * Blood loss or blood donation that exceeds 500 milliliters (mL) within 56 days prior to or at the screening visit or donation of any amount of blood from the screening visit until admission to the clinical research unit (CRU). * Healthy participants: * Clinical laboratory values outside the reference range during the screening period or on Day ˗1 and considered clinically significant by the investigator * Alanine aminotransferase or aspartate aminotransferase \> 1.5 \* the upper limit of normal (ULN) or bilirubin ≥ 1.0 \* the ULN. * Participants with hepatic impairment: * Participant with clinically significant laboratory values in the opinion of the investigator or outside the acceptable ranges or limits during the screening period. Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of BPN14770 | Predose up to 240 hours postdose |
| Maximum Observed Plasma Concentration (Cmax) of BPN14770 | Predose up to 240 hours postdose |
| Time Maximum Observed Plasma Concentration (Tmax) of BPN14770 | Predose up to 240 hours postdose |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Up to 15 days postdose |
Countries
United States
Contacts
STUDY_DIRECTORMedical Director
Shionogi Inc.
Outcome results
None listed